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Autoimmunity travelled from the theoretical roots planted by Burnet with the clonal
selection theory and the early finding of a mouse providing a test for the role of the
thymus as a source of forbidden clones. This chapter briefly reviews early work with
the NZB mouse and presents results of an analysis of associations between cytokines
and physical and psychometric parameters in systemic lupus erythematosus (SLE)
patients notmedicatedwith antidepressants. Some cytokines, particularly IFN-γ, relate
significantly to physical symptoms and anxiety. We conclude with the speculation that
anxiety is linked to innate immunity and more severe neuropsychiatric disease in SLE
to adaptive immunity.




The development of a simple test that en-
abled the detection of antibodies against red
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blood cells by Coombs in the 1940s1 became
an extremely valuable tool in the diagnosis
of autoimmune disease in humans and in the
first experimental model of spontaneous sys-
temic lupus erythematosus (SLE)—the New
Zealand Black (NZB)mouse.2 TheNZBmouse
became, in turn, an extremely valuable tool
for testing Burnet’s clonal selection theory of
antibody production.3 According to the bio-
graphical memoir in the Australian Academy
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of Science,4 of his contributions to immunol-
ogy, Burnet, with Dr. Margaret Holmes,5 de-
voted the last few years of his life at the bench
exploring various aspects of the biology and
immunopathology of thesemice, which sponta-
neously develop a high incidence of haemolytic
anaemia of an autoimmune type, at an early
age, and other signs recalling human systemic
lupus erythematosus.2 Having shown that the
anaemia could be transferred to young isol-
ogous mice by transfer of spleen cells from
older mice Burnet andHolmes showed that the
affected mice developed characteristic thymic
lesions.”5
The appearance of germinal centers in sev-
eral organs, including the thymus, was con-
firmed later by East, de Sousa, and Parrott (re-
viewed in Ref. 6). The notion that the thymus
was the source of forbidden clones influenced
the decision to thymectomize one case of severe
SLE.7 Two years later, East et al. showed that
neonatal thymectomy in NZB mice had no ef-
fect on the development of the SLE-like pathol-
ogy resulting in some cases in worsening of the
condition.8 Today, it has become evident that
the benefits of thymectomy in autoimmune dis-
ease are questionable, and there are several re-
ports of development of SLE in thymectomized
myasthenia gravis patients.9,10
Why start this chapter with reference to such
old, seemingly outdated frontiers in autoim-
munity? They illustrate well the difference be-
tween tool and theory and the approach of the
two old explorers—Coombs, whose contribu-
tion is still of practical usefulness today, and
Burnet, whose theoretically inspired contribu-
tions in immunology led him to share theNobel
Prize for Physiology and Medicine with Sir Pe-
ter Medawar in 1960, and whose convictions
without full experimental testing came to pre-
cipitous action on the part of surgeons. Analysis
of the tissues of the thymectomized animals by
one of us very soon showed that in some cases
of partial thymectomy the animals actually de-
veloped more severe disease, indicating already
then that the balance between thymus-derived
cell populations might be much more complex
than anticipated at the time. That of course
proved to be the case.
The New Explorers
In the mid-1960s, the discoveries of the func-
tion of the thymus and of thymus-derived cell
populations demonstrating the existence of a
cellular in addition to the well-established hu-
moral immunity built a relatively simple image
of the immune system consisting of two main
populations. T and B cells were shown to have
different origins and distinct destinations in the
peripheral lymphoid organs. This view of the
immune system would absorb the attention of
immunologists for years. It is to a certain extent
shattered into many more puzzle pieces today
as tools gained an exquisite degree of precision
in the definition of cell populations within the
T and B cell families. This degree of precision
reached not just the cell surface marker level
with the discovery of monoclonal antibodies11
and technical achievements in fluorescent acti-
vating cell sorting, but—and of particular inter-
est to this chapter—extended to the definition
of activation markers preferentially associated
with cell subsets and their respective products,
the cytokines, at the cell and molecular levels.12
It can thus be said that larger-than-life figures
like Coombs, Burnet, or Medawar are being
replaced by an increasing array of tools acting
themselves as explorers, building a cutting-edge
frontier in a hypothesis-free world, where infec-
tion itself is diminishing but all roads lead to the
clinic.
New Frontiers in Autoimmunity
The importance of situations in which the
activation of the immune system occurs in the
absence of the purpose of fighting an infec-
tion or rejecting an allograft cannot be un-
derestimated. In general, however, one feels
that other noninfectious diseases such as al-
lergy, atherosclerosis, obesity, and themetabolic
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syndrome are the focus of greater attention
than autoimmunity. Nevertheless, the availabil-
ity of disease models of spontaneous immune
activation without infection, like SLE, enables
us to redraw the cutting edge of the immune
system itself from new actions of innate immu-
nity products, the cytokines, as illustrated by
the results of the study described in the next
section.
The Present Study: A
Little-explored Frontier
SLE continues to be a significant model of a
“strictly immunological” disease. Our interest
focused on the neuropsychiatric frontier. De-
pression and anxiety are reported in SLE and
have been related to strong psychosocial influ-
ences or regarded as a result of the disease im-
munological dysfunction.
The results to be presented in this brief re-
view refer only to 9 SLE nonmedicated fe-
male patients between the ages of 21 and 60.
They are part of a larger study of SLE patients
with and without depression, psychiatric pa-
tients with major and minor depression, and
healthy controls within the same age range
(20–65) in a total of 99 women who submit-
ted to psychosocial evaluation. The evaluation
consisted of a battery of tests that included,
for diagnosis of major depression according to
DSM-IV criteria, a semistructured interview,
the Diagnostic Interview for Genetic Studies
(DIGS).13 The Mini Mental State Examina-
tion (MMSE) was used to assess basic cogni-
tive measures in all subjects.14 The Portuguese
version of the original Short Form Health Sur-
vey (SF-36) was used to assess health-related
quality of life.15,16 The degree to which the
participants appraised their lives as being stress-
ful during the previous month was assessed us-
ing the 10-item version of the Perceived Stress
Scale (PSS), providing a more subjective evalu-
ation of stress than life events scores.17 In order
to evaluate current severity of depression and
anxiety, the Hospital Anxiety and Depression
Scale (HADS) was used.18 Affective State eval-
uationwas done using the PANAS ( Positive and
Negative Affect Schedule).19 Clinical indices
of disease were based on SLEDAI (Systemic
Lupus Erythematosus Disease Activity Index)
and SLLIC/ACR (Systemic Lupus Interna-
tional Collaborative Clinics/American College
of Rheumatology Damage Index). Determina-
tion of cytokines was done for IFN-γ, IL-6,
IL-8, IL-10, and TNF-α, in peripheral blood
by flow cytometry using a Cytomics FC500
flow cytometer (Beckman-Coulter, Brea, CA)
and a BMS710FF humanTh1/Th2 10plexKit
I (BenderMedSystems GmBH, Vienna, Aus-
tria). Cytokine levels, as expected, were higher
in the SLE patients than in controls (Table 1).
The differences reached statistical significance
in IFN-γ, IL-6, and IL-5.
As shown in Figure 1, negative correlations
were seen between IFN-γ and Role Func-
tion Physical, Role Function Emotional, Social
Function and Mental Health in the 9 SLE pa-
tients without major depression and without
medication (Fig. 1). Similar negative correla-
tions were observed with IL-8 (data not shown).
One most interesting result was the finding
of a clear separation between the positive cor-
relation of IFN-γ and IL8 (not shown) with
anxiety, but not with depression (Fig. 2). To our
knowledge this is the first demonstration of an
association between IFN-γ levels and anxiety in
an immune activation disease. Furthermore, it
is of some interest to have found that IL-8 is the
second cytokine to relate to an equal number of
measures of psychological function. The results
also showed that TNF-α followed with nega-
tive correlations with Physical Function, Men-
tal Health and positively with Anxiety (data
not shown) in SLE patients without depression.
Finally, IL-6 correlated significantly with Emo-
tional Function and IL-10 with Physical Func-
tion, indicating that subtle differencesmay exist
between the cytokine targets (data not shown).
No correlations were found between psychoso-
cial measures and cytokine levels in depressed
patients taking medication and in controls.
Interestingly, a trend was detected of higher
cytokine levels in SLE patients with major
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TABLE 1. Cytokine Levels in a Group of 9 Patients Without Depression Who Are Not Taking Anti-
depressants or Corticoids Confirm Immune Activation Nature of SLE
Group IFN-γa IL-1β IL-2 IL-6a TNF-α TNF-β IL-8 IL-4 IL-5a IL-10
SLE 129.2b 134.3 138.1 108.1 183.8 118.1 127.6 169 158.1 157
(n = 9) ± 63.7 ± 66.9 ± 70.3 ± 41.1 ± 168.7 ± 47.5 ± 58.7 ± 91.9 ± 80.2 ± 103
Controls 79.6 93.3 82 75.4 104.3 78.7 84.7 108.9 93.7 88.9
(n = 31) ± 53.2 ± 61.5 ± 48.9 ± 37.6 ± 85.5 ± 43.2 ± 49.1 ± 94.6 ± 58.2 ± 55
aP < 0.05; bMean ± Standard deviation
Figure 1. (A–D) Negative correlations between IFN-γ and Role Function Physical, Role Function Emo-
tional, Social Function and Mental Health.
depression when medicated with anti-
depressants, statistically significantly different
in IL-8 (P = .010), IL-10 (P = .017), and
TNF-α (P = .018), when compared to non-
antidepressant medicated patients of the same
group (nonparametric Mann-Whitney test).
The effectiveness of antidepressants has been
vividly questioned recently as a “myth based
on a thousand clinical trials.”20
The interactions seen between cytokine ex-
pression and HADS A scores indicate that the
immune system through some cytokines may
have a role in the pathophysiology of anxiety in
SLE, in the absence of psychiatric disorder.
Our results support further the results of
other studies with ovarian cancer patients and
burn-out school teachers in which pro- and
anti-inflammatory cytokine levels have been di-
rectly linked to the development of anxiety.21,22
Where Old and New
Explorers Meet
The novel contribution of the results re-
ported here is the significant association of
cytokine levels with anxiety in SLE patients
without major depression and not receiving
medication. In 1996 Schrott and Crnic had
compared the behavior of hybrids of the orig-
inal NZB mouse first studied by Burnet—
the NZBx NZW F1 (B/W) hybrid and NZW
mice—that do not develop autoimmune dis-
ease: “B/W mice were less active at both
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Figure 2. (A, B) Positive correlations between
IFN-γ and anxiety and no correlation with depression
in SLE-NMD patients without medication.
ages, suggesting a genetic component to this
behavioral difference. Anxiety behavior and
exploratory behavior did not differ between
B/W and NZW mice at 6 weeks; however, at
12 weeks B/W mice displayed more anxiety
behavior and less exploratory behavior, indi-
cating that these behaviors were related with
the development of autoimmune disease. Prior
experience with these tasks increased anxiety
behavior in B/W but not NZW mice, suggest-
ing that B/W mice may be more sensitive to
anxiogenic experiences.”23
Later, to confirm the relationship be-
tween disease progression and development of
behavioral abnormalities, Schrott and Crnic24
subjected B/W and nonautoimmune NZW
mice to the chronic treatment with a solu-
ble IFN-γ receptor (sIFN-γ R), a treatment
known to retard autoimmune disease progres-
sion, or vehicle, beginning at 6 weeks of age:
“After 6 weeks of treatment, elevated plus maze
and novel object testing revealed that although
sIFN-γ R treated B/W mice still differed from
NZWmice, chronic sIFN-γR treatment signif-
icantly retarded the development of behavioral
abnormalities in theB/Wmice,while theNZW
mice were not affected by this treatment. sIFN-
γ R treated B/W mice were more active in
both the plus maze and novel object tasks, and
displayed less plus maze anxiety behavior and
more exploratory activity in the novel object
task compared to vehicle treated B/W mice.”
The authors concluded in 1998 that “the re-
sults added to the growing evidence that lupus-
associated behavioral abnormalities are a direct
effect of the autoimmune disease.”24
Concluding Remarks
The present chapter illustrates well how SLE
as an established autoimmune disease pro-
vides an excellent experimental and clinical
model for testing in the clinic today what was
cutting-edge observation in experimental ani-
mals yesterday. The frontiers between these two
worlds are now being pushed by cytokines as in
the 1960s they were pushed by theories trying
to explain self-tolerance. At both ends of the
rainbow of time, the thymus, thymus-derived
populations and cytokines seem unquestion-
ably critical to the development of the autoim-
mune disease and of anxiety.
We wish to conclude with a “cutting-edge
speculation.” Others studying SLE have shown
an association of antibodies directed against
N-methyl-D-aspartate receptor subunit NR2
(anti-NR2) in cerebrospinal fluid (CSF) of pa-
tients with neuropsychiatric manifestations in
systemic lupus erythematosus.25 The specula-
tion consists of proposing that cytokines as the
expression of innate immunity are associated
with anxiety, and that autoantibodies as the ex-
pression of adaptive immunity are associated
with more severe neuropsychiatric symptoms,
including depression.
It is fortunate that one of us has been at
both ends of the rainbow to witness and be
part of the progress of knowledge in this field.
It feels slow, but it seems steady. It makes
one wonder if immune-based therapies should
not be extended from cutting-edge experimen-
tal findings to the clinic, and vice versa—if
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cutting-edge findings in the clinic should not
be more thoroughly tested experimentally.
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